Summary

The Age-Related Macular Degeneration (AMD) Drugs market is projected to reach USD 17.37 Billion from 2029 USD 10.46 Billion in 2024 growing at a CAGR of 10.7% during the forecast period of 2024-2029.
Major pharmaceutical companies have reported a 2 fold increase in the geriatric population (above 60 years of age) by 2050, and this increase will have an impact on the number of AMD cases as AMD is associated with old age. Lifestyle factors such as smoking, diet, and physical activity also significantly influence AMD risk. For instance, studies have shown that smoking can accelerate the onset of AMD by an average of 5.5 years. According to the Macular Society (UK), smokers are likely to develop AMD up to 10 years earlier than non-smokers. Leading ophthalmologists from the UAE and UK have reported a decrease in the onset age of AMD and concluded that unhealthy lifestyle habits can bring down this age further by the next decade. Researchers from Japan conducted research to examine the effects of alcohol on AMD and concluded that moderate to heavy alcohol consumption increases the risk of early AMD. Similarly, a higher body mass index (BMI) is associated with an increased risk of both early and late AMD, as obesity and lack of physical activity are linked to increased oxidative stress and inflammation, contributing to AMD development. Rising incidences of AMD are driving companies to expand their drug pipeline and seek fast-track designations to advance their products' availability. For instance, in 2021 Opthea Limited received fast-track designation for its pipeline drug OPT-302 developed for the treatment of patients with wet AMD, advancing its development process. Similarly in 2023, Adverum Biotechnology received an Innovation Passport from the UK’s MHRA for its pipeline drug Ixo-vec (ixoberogene soroparvovec), helping to speed up patient access and regulatory support in the UK. These developments along with a rising number of AMD cases are projected to increase the demand for AMD drugs in the market.
“Vabysmo drug is set to register the highest growth during 2024-2029 in the Age-Related Macular degeneration (AMD) drugs market”
Based on products the Age-Related Macular Degeneration (AMD) drugs market is segmented into Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, and other products including Beovu, Conbercept, Byooviz, and Izervay among others. Vabysmo (faricimab-svoa) is set to register the highest growth rate during the forecast period of 2024-2029, owing to the positive feedback received from patients and ophthalmologists for the treatment of AMD. The rising adoption of the drug is also supported by the 4x increase in the revenue of the drug from 2022 to 2023. Studies conducted to test the efficacy and tolerability of the drug have concluded that the drug is well tolerated in people with retinal disorders and can preserve vision while reducing the frequency of injections elevating the treatment burden of the patients. The drug is also used for the treatment of patients who showed resistance to the treatment from Eylea (aflibercept) and has significant improvement in visual acuity.
“Hospitals to witness the high growth in the AMD drugs market by End User”
Based on end users, the age-related macular degeneration (AMD) drugs market is segmented into hospitals, specialty centers, and long-term care facilities. Hospitals are projected to witness the highest growth rate during the forecast period of 2024-2029. This growth can be attributed to factors such as the ability of hospitals to provide comprehensive care to patients through advanced healthcare infrastructure and specialized treatment facilities. Additionally, hospitals are more abundant than any other end user (Specialty centers and Long-term care facilities) and modern hospitals are generally multispeciality in nature offering specialized treatment. Hospitals often collaborate with long-term care (LTC) facilities to provide support such as ophthalmologists for the treatment of individuals living in the care facility. Moreover, hospitals also partner with pharmaceutical companies to ensure an optimal supply of AMD drugs for the patients.
“Biologics segment accounted for the highest growth rate in the Age-Related Macular Degeneration (AMD) drugs market by approval type”
Based on approval type, the age-related macular degeneration (AMD) drugs market is segmented into biologics and biosimilars. During the forecast period of 2024-2029, biologics are projected to register the highest growth in the AMD drugs market by approval type. This high growth can be attributed to the increase in the number of approvals for biologics such as Vabysmo, Eylea HD, Syfovre, and Izervay, among others, for the treatment of AMD. Moreover, as these drugs are recently approved they are protected by patents and generally prevent biosimilar entry into the market. Additionally, improved reimbursement policies and comprehensive insurance coverage offered for biologics generally deter patients and ophthalmologists from choosing biosimilars over biologics. New innovative companies are also developing novel biologics for treating various forms of AMD supporting the growth of this segment.
“North America: The fastest-growing country in the Age-Related Macular Degeneration (AMD) drugs market”
The Age-Related Macular Degeneration (AMD) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is projected to register the highest CAGR during the forecast period. Factors such as rising AMD cases due to an increase in the geriatric population and accompanied by unhealthy lifestyle and dietary habits, and increasing pharmaceutical R&D spending, by major pharmaceutical and biotechnology companies present in the region, to develop novel therapies and drug delivery systems for AMD disease are driving the growth of AMD drugs in the region. Additionally, growing public-private partnerships, increasing government support and improved reimbursement policies further support the growth of the AMD drugs market in this region.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side -70% and Demand Side – 30%
• By Designation: Managers -45%, CXOs and Directors -30%, and Executives – 25%
• By Region: North America-35%, Europe -25%, Asia-Pacific -15%, Latin America-10%, Middle East-10% and Africa-5%
Lists of Companies Profiled in the Report:
• Regeneron Pharmaceuticals Inc. (US)
• Bayer AG (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Apellis Pharmaceuticals (US)
• Coherus BioSciences (US)
• Astellas Pharma Inc. (Japan)
• Biogen (US)
• STADA Arzneimittel AG (Germany)
• Formycon AG (Germany)
• Biocon. (India)
• Outlook Therapeutics, Inc. (US)
• Intas Pharmaceuticals Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Chengdu Kanghong Biotech Company (China)
• Sandoz Group AG (Switzerland)
• Stealth BioTherapeutics Inc. (US)
• Ocular Therapeutix, Inc. (US)
• Opthea Limited (Australia)
• Kodiak Sciences Inc. (US)
• Innovent Biologics, Inc. (China)
• Bio-Thera Solution (China)
• Alvotech (Iceland)
• Alteogen Inc. (South Korea)
• Shanghai Henlius Biotech, Inc. (China)
• Amgen Inc. (US)
• Ocumension Therapeutics. (China)
• Adverum Biotechnologies, Inc. (US)
Research Coverage:
This report provides a detailed picture of the age-related macular degeneration (AMD) drugs market. It aims at estimating the size and future growth potential of the market across different segments, such as products, molecules, type of AMD, approval type, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing risk of AMD due to changing lifestyle and dietary habits, Steady development and approvals of drugs and Favorable reimbursement and insurance policies), restraints (Off-Label Use of Drugs), opportunities (Shifting Focus on New Drug Modalities, Rapidly expanding market in developing countries, Need to address dry age-macular degeneration and geographic atrophy), and challenges (Non-adherence to treatments) influencing the growth of the Age-Related Macular Degeneration (AMD) durgs market.

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new therapy launches in the Age-Related Macular Degeneration (AMD) drugs market.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various opportunities and developments across key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Age-Related Macular Degeneration (AMD) drugs market.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players like Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and Novartis AG (Switzerland) among others in the Age-Related Macular Degeneration (AMD) drugs market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 33
1.3 INCLUSIONS AND EXCLUSIONS 33
1.4 STUDY SCOPE 34
1.4.1 MARKETS COVERED 34
1.4.2 YEARS CONSIDERED 35
1.4.3 CURRENCY CONSIDERED 35
1.5 STAKEHOLDERS 35
1.6 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION DRUGS MARKET 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
2.1.1 SECONDARY DATA 38
2.1.2 PRIMARY DATA 38
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 43
2.3 MARKET GROWTH FORECAST 44
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 46
2.5 RESEARCH ASSUMPTIONS 46
2.6 RESEARCH LIMITATIONS 47
2.7 RISK ANALYSIS 47
3 EXECUTIVE SUMMARY 48
4 PREMIUM INSIGHTS 53
4.1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET OVERVIEW 53
4.2 NORTH AMERICAN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SHARE, BY APPROVAL TYPE AND COUNTRY, 2023 54
4.3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF
AMD, 2024 VS. 2029 (USD MILLION) 54
4.4 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2023 55
4.5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
GEOGRAPHIC GROWTH OPPORTUNITIES 55
 
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
5.2.1 DRIVERS 57
5.2.1.1 Changing lifestyle and dietary habits 57
5.2.1.2 Steady development and approvals of drugs 58
5.2.1.3 Favorable reimbursement and insurance policies 59
5.2.2 RESTRAINTS 60
5.2.2.1 Off-label use of drugs 60
5.2.3 OPPORTUNITIES 60
5.2.3.1 Shifting focus on new drug modalities 60
5.2.3.2 Rapidly expanding market in developing countries 61
5.2.3.3 Need to address dry age-related macular degeneration and geographic atrophy 62
5.2.4 CHALLENGES 63
5.2.4.1 Non-adherence to treatments 63
5.3 TECHNOLOGY ANALYSIS 64
5.3.1 KEY TECHNOLOGIES 64
5.3.1.1 Hybridoma technology 64
5.3.1.2 Recombinant DNA technology 64
5.3.1.3 Antibody engineering 65
5.3.2 ADJACENT TECHNOLOGIES 65
5.3.2.1 Tissue engineering (scaffold technology) 65
5.3.2.2 Artificial intelligence 66
5.3.2.3 Optogenetic technology 66
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67
5.5 PRICING ANALYSIS 67
5.5.1 AVERAGE SELLING PRICING OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE) 68
5.5.2 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION 68
5.5.3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER 69
5.6 VALUE CHAIN ANALYSIS 70
5.7 SUPPLY CHAIN ANALYSIS 72
5.8 ECOSYSTEM ANALYSIS 73
5.9 PATENT ANALYSIS 75
5.10 REGULATORY ANALYSIS 77
5.10.1 REGULATORY LANDSCAPE 77
5.10.1.1 US 78
5.10.1.2 Europe 79
5.10.1.3 Emerging economies 79
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
5.11 PORTER’S FIVE FORCES ANALYSIS 83
5.11.1 INTENSITY OF COMPETITIVE RIVALRY 84
5.11.2 BARGAINING POWER OF SUPPLIERS 85
5.11.3 BARGAINING POWER OF BUYERS 85
5.11.4 THREAT OF SUBSTITUTES 85
5.11.5 THREAT OF NEW ENTRANTS 85
5.12 KEY CONFERENCES AND EVENTS, 2024–2025 86
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 87
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 87
5.13.2 BUYING CRITERIA 87
5.14 INVESTMENT/FUNDING ACTIVITY 89
5.15 PIPELINE ANALYSIS 89
5.16 CASE STUDY ANALYSIS 92
5.16.1 IMPROVED EFFICACY OF RGX-314 FOR WET AGE-RELATED
MACULAR DEGENERATION TREATMENT 92
5.16.2 ENHANCED EFFICACY OF EYLEA HD FOR WET AGE-RELATED
MACULAR DEGENERATION TREATMENT 92
5.16.3 HIGHER EFFICACY AND SAFETY OF FARICIMAB FOR NEOVASCULAR
AGE-RELATED MACULAR DEGENERATION TREATMENT 92
5.17 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET 93
6 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY PRODUCT 95
6.1 INTRODUCTION 96
6.2 EYLEA & EYLEA HD 96
6.2.1 HIGHER PREFERENCE BY OPHTHALMOLOGISTS AND PATIENTS
TO SPEED UP GROWTH 96
6.3 LUCENTIS 100
6.3.1 PROVEN ABILITY TO IMPROVE VISUAL ACUITY AND RETINAL
THICKNESS TO FAVOR GROWTH 100
6.4 VABYSMO 104
6.4.1 FAVORABLE APPROVAL FROM GOVERNMENT AUTHORITIES
TO SUSTAIN GROWTH 104
6.5 SYFOVRE 107
6.5.1 INCREASING PREVALENCE OF ADVANCED DRY AGE-RELATED
MACULAR DEGENERATION TO BOOST MARKET 107
6.6 OTHER PRODUCTS 111
 
7 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY MOLECULE 114
7.1 INTRODUCTION 115
7.2 AFLIBERCEPT 115
7.2.1 HIGHER EFFICIENCY IN TREATING RETINAL DISORDERS
TO EXPEDITE GROWTH 115
7.3 FARICIMAB 119
7.3.1 FAVORABLE ADOPTION AND OUTCOMES OF RESEARCH
STUDIES TO AUGMENT GROWTH 119
7.4 RANIBIZUMAB 122
7.4.1 ENHANCED RESULTS COMPARED TO LASER TREATMENT TO DRIVE MARKET 122
7.5 PEGCETACOPLAN 126
7.5.1 HIGHER ADOPTION IN TREATING GEOGRAPHIC ATROPHY TO
CONTRIBUTE TO GROWTH 126
7.6 OTHER MOLECULES 129
8 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY APPROVAL TYPE 133
8.1 INTRODUCTION 134
8.2 BIOLOGICS 134
8.2.1 HIGHER CLINICAL VALIDATION AND REGULATORY ADVANTAGES
TO SUPPORT GROWTH 134
8.3 BIOSIMILARS 138
8.3.1 LOW DEVELOPMENT AND APPROVAL TO FAVOR MARKET GROWTH 138
9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY TYPE OF AMD 142
9.1 INTRODUCTION 143
9.2 WET AMD 143
9.2.1 GROWING GERIATRIC POPULATION TO FACILITATE GROWTH 143
9.3 DRY AMD 147
9.3.1 INCREASED RESEARCH & DEVELOPMENT EFFORTS TO PROMOTE GROWTH 147
10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY END USER 151
10.1 INTRODUCTION 152
10.2 HOSPITALS 152
10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO STIMULATE GROWTH 152
10.3 LONG-TERM CARE FACILITIES 156
10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET 156
10.4 SPECIALTY CENTERS 159
10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH 159
11 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION 163
11.1 INTRODUCTION 164
11.2 NORTH AMERICA 164
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 168
11.2.2 US 169
11.2.2.1 Rising investment in healthcare research & development
to propel market 169
11.2.3 CANADA 172
11.2.3.1 Favorable government initiatives to aid market growth 172
11.3 EUROPE 174
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 176
11.3.2 GERMANY 178
11.3.2.1 Rising focus on clinical research with public-private partnerships to augment growth 178
11.3.3 UK 181
11.3.3.1 Ongoing technological advancements to promote growth 181
11.3.4 FRANCE 183
11.3.4.1 Growing investments in funding healthcare and allied technology to foster growth 183
11.3.5 ITALY 186
11.3.5.1 Comprehensive treatment coverage and funding for new therapies to fuel market 186
11.3.6 SPAIN 189
11.3.6.1 Growing number of collaborative projects to favor market growth 189
11.3.7 NETHERLANDS 192
11.3.7.1 Increasing focus of clinical trials on biomarkers and hereditary conditions to drive market 192
11.3.8 REST OF EUROPE 194
11.4 ASIA PACIFIC 197
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 200
11.4.2 CHINA 201
11.4.2.1 Strategic drug approvals to support market growth 201
11.4.3 JAPAN 204
11.4.3.1 Advanced healthcare infrastructure to encourage growth 204
11.4.4 INDIA 206
11.4.4.1 Regulatory reforms and aging population to boost market 206
11.4.5 AUSTRALIA 209
11.4.5.1 Increasing disease incidence and evolving treatment options to facilitate growth 209
 
11.4.6 SOUTH KOREA 212
11.4.6.1 Supportive regulatory environment to boost market 212
11.4.7 REST OF ASIA PACIFIC 214
11.5 LATIN AMERICA 216
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 219
11.5.2 BRAZIL 220
11.5.2.1 Increasing rate of visual impairment to sustain growth 220
11.5.3 MEXICO 223
11.5.3.1 Growing research initiatives for alternative medicines and nano-based drug delivery system to speed up growth 223
11.5.4 REST OF LATIN AMERICA 225
11.6 MIDDLE EAST 227
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 230
11.6.2 GCC COUNTRIES 231
11.6.2.1 Saudi Arabia 233
11.6.2.1.1 Sustained health coverage and biosimilar drug approvals to propel market 233
11.6.2.2 UAE 235
11.6.2.2.1 Increasing focus on technological advancements, ongoing research, and government initiatives to support growth 235
11.6.2.3 Other GCC Countries 238
11.6.3 REST OF MIDDLE EAST 240
11.7 AFRICA 243
11.7.1 GROWING PREVALENCE OF PATIENT ADVOCACY GROUPS AND REGULATORY IMPROVEMENTS TO DRIVE MARKET 243
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 245
12 COMPETITIVE LANDSCAPE 247
12.1 OVERVIEW 247
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 247
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET 248
12.3 REVENUE ANALYSIS, 2021–2023 250
12.4 MARKET SHARE ANALYSIS, 2023 251
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 253
12.5.1 STARS 254
12.5.2 EMERGING LEADERS 254
12.5.3 PERVASIVE PLAYERS 254
12.5.4 PARTICIPANTS 254
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 256
12.5.5.1 Company footprint 256
12.5.5.2 Molecule footprint 257
12.5.5.3 Approval footprint 258
12.5.5.4 Type of AMD footprint 259
12.5.5.5 Region footprint 260
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 261
12.6.1 PROGRESSIVE COMPANIES 261
12.6.2 RESPONSIVE COMPANIES 261
12.6.3 DYNAMIC COMPANIES 261
12.6.4 STARTING BLOCKS 261
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 263
12.7 COMPANY VALUATION AND FINANCIAL METRICS 265
12.7.1 COMPANY VALUATION 265
12.7.2 FINANCIAL METRICS 266
12.8 BRAND/PRODUCT COMPARISON 267
12.9 COMPETITIVE SCENARIO 268
12.9.1 PRODUCT LAUNCHES & APPROVALS 268
12.9.2 DEALS 270
12.9.3 EXPANSIONS 271
13 COMPANY PROFILES 272
13.1 KEY PLAYERS 272
13.1.1 F. HOFFMANN-LA ROCHE LTD 272
13.1.1.1 Business overview 272
13.1.1.2 Products offered 273
13.1.1.3 Recent developments 274
13.1.1.3.1 Product launches & approvals 274
13.1.1.4 MnM view 275
13.1.1.4.1 Right to win 275
13.1.1.4.2 Strategic choices 275
13.1.1.4.3 Weaknesses and competitive threats 275
13.1.2 REGENERON PHARMACEUTICALS INC. 276
13.1.2.1 Business overview 276
13.1.2.2 Products offered 277
13.1.2.3 Recent developments 277
13.1.2.3.1 Product launches & approvals 277
13.1.2.4 MnM view 277
13.1.2.4.1 Right to win 277
13.1.2.4.2 Strategic choices 278
13.1.2.4.3 Weaknesses and competitive threats 278
13.1.3 NOVARTIS AG 279
13.1.3.1 Business overview 279
13.1.3.2 Products offered 281
13.1.3.3 Recent developments 281
13.1.3.3.1 Product launches & approvals 281
13.1.3.3.2 Deals 282
13.1.3.4 MnM view 282
13.1.3.4.1 Right to win 282
13.1.3.4.2 Strategic choices 282
13.1.3.4.3 Weaknesses and competitive threats 282
13.1.4 BAYER AG 283
13.1.4.1 Business overview 283
13.1.4.2 Products offered 284
13.1.4.3 Recent developments 285
13.1.4.3.1 Product launches & approvals 285
13.1.4.4 MnM view 285
13.1.4.4.1 Right to win 285
13.1.4.4.2 Strategic choices 285
13.1.4.4.3 Weaknesses and competitive threats 286
13.1.5 APELLIS PHARMACEUTICALS 287
13.1.5.1 Business overview 287
13.1.5.2 Products offered 287
13.1.5.3 Recent developments 288
13.1.5.3.1 Product launches & approvals 288
13.1.5.3.2 Deals 288
13.1.5.4 MnM view 289
13.1.5.4.1 Right to win 289
13.1.5.4.2 Strategic choices 289
13.1.5.4.2.1 Weaknesses and competitive threats 289
13.1.6 ASTELLAS PHARMA INC. 290
13.1.6.1 Business overview 290
13.1.6.2 Products offered 291
13.1.6.3 Recent developments 292
13.1.6.3.1 Product launches & approvals 292
13.1.6.3.2 Deals 292
13.1.7 STADA ARZNEIMITTEL AG 293
13.1.7.1 Business overview 293
13.1.7.2 Products offered 294
13.1.7.3 Recent developments 295
13.1.7.3.1 Product launches & approvals 295
13.1.7.3.2 Deals 296
13.1.8 BIOGEN 297
13.1.8.1 Business overview 297
13.1.8.2 Products offered 298
13.1.8.3 Recent developments 299
13.1.8.3.1 Product launches & approvals 299
 
13.1.9 FORMYCON AG 301
13.1.9.1 Business overview 301
13.1.9.2 Products offered 302
13.1.9.3 Recent developments 303
13.1.9.3.1 Product launches & approvals 303
13.1.9.3.2 Deals 304
13.1.10 COHERUS BIOSCIENCES 305
13.1.10.1 Business overview 305
13.1.10.2 Products offered 305
13.1.10.3 Recent developments 306
13.1.10.3.1 Products launches & approvals 306
13.1.10.3.2 Other developments 306
13.1.11 BIOCON 307
13.1.11.1 Business overview 307
13.1.11.2 Product offered 308
13.1.11.3 Recent developments 309
13.1.11.3.1 Product launches & approvals 309
13.1.11.3.2 Deals 309
13.1.12 OUTLOOK THERAPEUTICS, INC. 310
13.1.12.1 Business overview 310
13.1.12.2 Products offered 310
13.1.12.3 Recent developments 311
13.1.12.3.1 Product launches & approvals 311
13.1.12.3.2 Deals 311
13.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD. 312
13.1.13.1 Business overview 312
13.1.13.2 Products offered 313
13.1.13.3 Recent developments 314
13.1.13.3.1 Product launches & approvals 314
13.1.13.3.2 Deals 314
13.1.14 INTAS PHARMACEUTICALS LTD. 315
13.1.14.1 Business overview 315
13.1.14.2 Products offered 315
13.1.15 SANDOZ GROUP AG 316
13.1.15.1 Business overview 316
13.1.15.2 Products offered 317
13.1.15.3 Recent developments 318
13.1.15.3.1 Product launches & approvals 318
13.1.15.3.2 Deals 318
13.1.15.3.3 Expansions 318
 
13.1.16 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD. 319
13.1.16.1 Business overview 319
13.1.16.2 Products offered 319
13.2 OTHER PLAYERS 320
13.2.1 OCULAR THERAPEUTIX, INC. 320
13.2.2 OPTHEA LIMITED 321
13.2.3 KODIAK SCIENCES INC. 322
13.2.4 BIO-THERA 323
13.2.5 AMGEN INC. 323
13.2.6 ALVOTECH 324
13.2.7 STEALTH BIOTHERAPEUTICS INC. 325
13.2.8 ALTEOGEN INC. 326
13.2.9 OCUMENSION THERAPEUTICS 326
13.2.10 INNOVENT 327
13.2.11 SHANGHAI HENLIUS BIOTECH, INC. 327
14 APPENDIX 328
14.1 DISCUSSION GUIDE 328
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 332
14.3 CUSTOMIZATION OPTIONS 334
14.4 RELATED REPORTS 334
14.5 AUTHOR DETAILS 335